Greifswald University Hospital (German: Universitätsmedizin Greifswald) is a teaching hospital for the University of Greifswald's medical school. Greifswald University Hospital is owned and operated by a non-profit Anstalt des öffentlichen Rechts in cooperation with the university and serves as one of the primary hospitals in the state of Mecklenburg-Vorpommern. It also fills the function of a tertiary referral hospital for the health care region. For more information please visit their website.
Andreas GreinacherPrincipal Investigator
Dr. Andreas Greinacher, specialized for transfusion medicine, immunohematology and hemostasis, is full professor and head of the department of transfusion medicine and the thrombosis and hemostasis service at the Universitätsmedizin Greifswald, Germany.
His research interests are hereditary and immune mediated thrombocytopenias, especially heparin-induced thrombocytopenia and application of biophysics to understand molecular mechanisms of antigenicity of endogenous proteins.
He has identified the genetic basis of the HNA-3a antigen, an important cause of TRALI, developed a new treatment approach during the EHEC outbreak in Germany in 2011, and contributed to better understanding of heparin-induced thrombocytopenia.
He was the principal investigator of the studies leading to approval of recombinant hirudin as the first non-heparin/warfarin anticoagulant. During the last years, his work on vaccine-induced immune thrombotic thrombocytopenia (VITT) received major attention by the scientific community and the general public.
He has published more than 500 papers on these topics and has received several national and international awards.
Kathleen SellengAlternate to PI
Dr. Kathleen Selleng, specialized for transfusion medicine, immunohematology and hemostasis, is the head of the immunohematology laboratory of the institute of transfusion medicine, quality management officer for hemotherapy and senior consultant of the thrombosis and hemostasis service at the Universitätsmedizin Greifswald, Germany. Her main interest is the improvement of processes for patient care in major bleeding emergencies and immunohematology diagnostics.
She is involved in research for PF4 dependent immunothrombotic diseases like heparin-induced thrombocytopenia and Covid-19 vaccine induced thrombocytopenia as well as in the development of new blood products for transfusion.